Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860118 · ClinicalTrials.gov registry record
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 601
- Enrollment target
NCT01860118: Completed study, sponsored by University of Alabama at Birmingham.
NCT01860118 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 601 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01860118 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 601 participants
- Enrollment target
Study Summary
This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls, and 2) to determine if LRRK2 expression and/or phosphorylation are significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target effects for future LRRK2 inhibitor clinical trials.
Primary Outcome
Biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-06-21 |
What the finished NCT01860118 record still lists
NCT01860118 is an observational study that tracks outcomes without assigning an intervention. The registered 601 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01860118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01860118 about?
NCT01860118 is a clinical study titled "LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease". This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls, and 2) to determine if LRRK2 expression and/or phosphorylation are significantly lowered in the e...
What is the current status of trial NCT01860118?
This trial is currently completed. The enrollment target is 601 participants. The study started on 2013-01. Estimated completion is 2016-06-21.
Who is sponsoring clinical trial NCT01860118?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia